글로벌 이중특이항체 시장 – 2030년까지의 산업 동향 및 예측

이중특이항체 시장 분석 및 규모

예측 기간 동안 이중특이 항체 시장 성장을 촉진할 것으로 예상되는 주요 요인은 규제 당국의 특별 지정 증가입니다. 또한 여러 제약 산업에서 수행한 지속적인 임상 시험은 이중특이 항체 시장 성장을 더욱 촉진할 것으로 예상됩니다. 반면, 수많은 제약 회사에서 표적 치료법의 연구 및 개발에 대한 운영 수익 전망이 부족하여 타임라인 기간 동안 이중특이 항체 시장 성장을 더욱 방해할 것으로 예상됩니다.                       

Data Bridge Market Research는 2022년에 5억 4,500만 달러였던 이중 항체 시장이 2030년까지 1,782만 달러로 급증할 것이며 예측 기간 동안 6.9%의 CAGR을 보일 것으로 예상한다고 분석했습니다. 이는 시장 가치를 나타냅니다. "종양학"은 암 및 자가면역 질환과 같은 만성 질환의 발생률이 증가함에 따라 이중 항체 시장의 응용 분야를 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

이중특이항체 시장 범위 및 세분화

시장 정의

이중특이 항체는 두 개 이상의 항원 구별 요소가 혼합되어 단일 구조를 만드는 인공 단백질로 간주됩니다. 이중특이 항체는 동시에 두 개 이상의 표적에 결합할 수 있습니다.

이중특이항체 시장 동향

운전자

• 만성 질환의 유병률 증가

암과 자가면역 질환과 같은 만성 질환의 증가는 이중특이 항체 시장의 주요 원동력입니다. 이중특이 항체는 이러한 질병 영역에서 표적 치료와 개선된 치료 결과의 잠재력을 제공합니다.

• 생명공학 및 항체공학의 발전

생명공학 및 항체 공학 의 기술적 발전으로 특이성, 효능 및 약동학적 특성이 향상된 이중특이 항체의 개발이 가능해졌습니다. 이러한 발전은 치료적 응용 분야에서 이중특이 항체의 성장과 채택을 촉진합니다.

• 연구 개발 활동 증가

제약 회사와 학술 기관 모두에서 이중특이 항체의 연구 및 개발에 상당한 초점이 맞춰져 있습니다. 이는 혁신을 촉진하고, 이중특이 항체 후보의 파이프라인을 확장하며, 시장 성장을 촉진합니다.

• 개인화된 의학에 대한 수요 증가

개인화된 의학과 정밀 치료법으로의 전환은 이중특이적 항체에 대한 기회를 창출합니다. 이러한 항체는 특정 바이오마커 또는 경로를 표적으로 설계할 수 있어 개별 환자 특성에 따른 맞춤형 치료 접근 방식을 허용합니다.  

기회

• 확장된 치료적 응용 프로그램

Bispecific antibodies offer opportunities for therapeutic applications across a wide range of disease areas beyond oncology, including autoimmune disorders, infectious diseases, and cardiovascular diseases. Exploring new indications and expanding the therapeutic scope presents growth opportunities.

• Collaborations and Partnerships

Collaborations between pharmaceutical companies, academic institutions, and research organizations can facilitate the development and commercialization of bispecific antibodies. Partnerships and licensing agreements can leverage expertise, resources, and accelerate market penetration.

Restraints/Challenges

• Complex Manufacturing Processes

Bispecific antibody production involves intricate manufacturing processes, including specialized technologies and platforms. The complexity of manufacturing can pose challenges, impacting scalability, cost-effectiveness, and commercial viability.

• High Development Costs

The development of bispecific antibodies involves substantial investments in research, preclinical studies, and clinical trials. High development costs can act as a restraint, particularly for smaller biotechnology companies with limited financial resources.

• Immunogenicity Concerns

Bispecific antibodies can trigger immune responses, leading to the development of antidrug antibodies and potential loss of efficacy. Managing and mitigating immunogenicity concerns pose challenges in the development and clinical use of bispecific antibodies.

This bispecific antibody market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bispecific antibody market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In July 2022, Janssen Pharmaceutical reported announced that it has received conditional marketing authorisation for Teclistamab in patients with multiple myeloma from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). In addition, the business has submitted a Biologics Licence Application (BLA) to the US FDA in order to get clearance for its innovative medications. The approval is based on the favourable findings of a late-stage clinical trial that recommended increasing the drug's survival rates. The medicine is projected to be accessible in the market by the end of 2022, under the brand name Tecvalyi. Panther Healthcare launched the Smart Powered Stapler platform, which provides intelligent and automated control of tissue fixation, transection and resection across gastrointestinal (including bariatric), thoracic, colorectal, oncology, gynecology and other open and laparoscopic surgical procedures. The device was released in Europe, the Middle East, Africa, Asia and Latin America.
• In August 2018, an scientific research company based in Belgium i.e UCB pharma conducted a research on molecular factors in bispecific antibody multimerisation and revealed that the monomer level of single-chain variable fragment containing bispecific antibody format can be increased by conversion of the single chain variable to a disulfide- stabilized single chain variable fragment. through more uniform tissue compression and better stapling.

Global Bispecific Antibody Market Scope

The bispecific antibody market is segmented on the basis of type, mechanism of action, application, drugs, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets

Type

• Immunoglobulin G (IgG) such as Molecule
• Non Immunoglobulin G (IgG) such as Molecule

Mechanism of Action

• Bispecific Diabodies
• Bispecific T-Cell Engager Antibodies

Application

• Oncology
• Autoimmune Disease
• Others

Drugs

• Blinatumomab
• Catumaxomab
• Duligotumab
• Others

Route of Administration

• Oral
• Injectable

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

Bispecific Antibody Market Regional Analysis/Insights

The bispecific antibody market is analyzed, and market size information is provided by type, mechanism of action, application, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the bispecific antibody market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA)

North America dominates the bispecific antibody market due to the occurrence of major key players. Furthermore, the highest numbers of several cancers such as lung cancer, prostate cancer, breast cancer and cervical cancer will further boost the growth of the bispecific antibody market in the region during the forecast period. Asia-Pacific is projected to observe significant amount of growth of the bispecific antibody market due to the shortage of good healthcare facilities in the several countries. Moreover, the wide rise in the healthcare infrastructure like healthcare expenses, healthcare facility and health care budget and the increase in the penetration is further anticipated to propel the growth of the bispecific antibody market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Bispecific Antibody Market Share Analysis

The bispecific antibody market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to bispecific antibody market.

Some of the major players operating in the bispecific antibody market are:

• Adimab, Innovent Biologics, Inc (U.S.)
•  Affimed GmbH (China)
•  Amgen Inc (Germany
• AstraZeneca (U.K.)
•  Xencor (U.S.)
•  Sanofi (France)
•  F. Hoffmann-La Roche Ltd (Switzerland)
•  Regeneron Pharmaceuticals Inc (U.S.)
• Eli Lilly (U.S.)
• Pieris Pharmaceuticals, Inc(미국)
• Mereo BioPharma Group PLC(영국)
• Sobi, TG Therapeutics Inc(스웨덴)
• 메루스(네덜란드)
•  MacroGenics, Inc (미국)
•  젠맙 A/S(덴마크)
•  Emergent BioSolutions Inc(미국)
•  알테오젠(한국)
•  아스텔라스파마 주식회사(일본)
•  노바티스 AG(스위스)
• 셀진 코퍼레이션(미국)

SKU-50360